**Sunday, April 23**

|  |  |
| --- | --- |
|  |  |
|  | 08:30-10:00, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 101** | **Colorectal cancer patients – the challenge** |
|  |  |
|  | *Moderators: A. Cervantes (Valencia/ES), A. Gangi (Strasbourg/FR)* |
|  |  |
| 101.1    101.2    101.3    101.4  101.5    101.6 | Demographics and need for treatment  *A. Cervantes (Valencia/ES)*  Treatment strategies according to the new ESMO guidelines  *D. Arnold (Lisbon/PT)*  Who is the ideal candidate for liver surgery?  *to be announced*  Invited scientific paper  Local ablation in oligometastatic disease  *A. Gillams (London/UK)*  Intra-arterial therapies in advanced metastases  *P.L. Pereira (Heilbronn/DE)* |
|  |  |
|  |  |
|  | 10:30-12:00, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 201** | **Immunotherapy for cancer** |
|  |  |
|  | *Moderators: J.-F.H. Geschwind (New Haven, CT/US), P. Sarobe (Pamplona/ES)* |
|  |  |
| 201.1    201.2    201.3    201.4    201.5 | Cancer and immune reaction  *J.J. Lasarte (Pamplona/ES)*  Immunoscore: is it more relevant than TNM?  *J. Rodríguez (Pamplona/ES)*  Checkpoint inhibitors  *M. Fuchs (Munich/DE)*  Tumour exosomes – determination of organotropic metastases  *B. Costa-Silva (Lisbon/PT)*  IO and immunotherapy in cancer  *J.P. Erinjeri (New York, NY/US)* |
|  |  |
|  |  |
|  | 10:30-12:00, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 202** | **Colorectal cancer and IO: where is the evidence?** |
|  |  |
|  | *Moderator: P. Gibbs (Melbourne, VIC/AU)* |
|  |  |
| 202.1    202.2    202.3    202.4    202.5 | CLOCC trial in detail  *O.M. van Delden (Amsterdam/NL)*  Evidence for surgery as a curative treatment  *A. Denys (Lausanne/CH)*  SIRFLOX trial in detail  *P. Gibbs (Melbourne, VIC/AU)*  Does progression-free survival translate into overall survival?  *R. Sharma (London/UK)*  Evidence in endpoints for IO in CRC mets  *R. Salem (Chicago, IL/US)* |
|  |  |
|  |  |
|  | 10:30-12:00, HDT Room |
|  | **Hands-on Device Training** |
| **TA-HDT 1** | **Tumour ablation – Radiofrequency** |
|  |  |
|  | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|  |  |
|  |  |
|  | 13:00-14:30 |
|  | **Satellite Symposia** |
|  |  |
|  |  |
|  | 15:00-16:30, Main Auditorium |
|  | **Multidisciplinary Tumour Board** |
| **MTB 401** | **CRC metastases – beyond the guidelines** |
|  |  |
|  | *Coordinator: T.K. Helmberger (Munich/DE)* |
|  |  |
|  | *Panellists: D.J. Breen (Southampton/UK), A. Cervantes (Valencia/ES),*  *T. de Baère (Villejuif/FR), C.R. Ferrone (Boston, MA/US)* |
|  |  |
|  |  |
|  | 15:00-16:30, Auditorium 2 |
|  | **Technical Focus Session** |
| **TF 402** | **Cutting-edge developments** |
|  |  |
|  | *Moderators: K. Malagari (Athens/GR), J. Ricke (Magdeburg/DE)* |
|  |  |
| 402.1    402.2    402.3    402.4  402.5    402.6 | Drug-eluting particles  *R. Duran (Lausanne/CH)*  Thermal ablation  *L. Crocetti (Pisa/IT)*  Radioembolisation  *M. van den Bosch (Utrecht/NL)*  Invited scientific paper  Intratumoural immunotherapy and viral therapy  *L. Tselikas (Villejuif/FR)*  Immunotherapy plus ablation or DEB-TACE  *B.J. Wood (Bethesda, MD/US)* |
|  |  |
|  |  |
|  | 15:00-16:30, HDT Room |
|  | **Hands-on Device Training** |
| **TA-HDT 2** | **Tumour ablation – Radiofrequency** |
|  |  |
|  | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|  |  |
|  |  |
|  | 17:00-18:30, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 501** | **Follow the colorectal cancer patients: quality and efficacy** |
|  |  |
|  | *Moderators: A. Adam (London/UK), B. Gebauer (Berlin/DE)* |
|  |  |
| 501.1    501.2    501.3    501.4    501.5 | What are the guidelines?  *R. Vera (Pamplona/ES)*  Does expensive and short-term imaging follow-up affect the outcome?  *R.G.H. Beets-Tan (Amsterdam/NL)*  PET-CT: a critical review  *N. Schäfer (Lausanne/CH)*  PRO, PCO and PREM – what do they tell us?  *P. Reimer (Karlsruhe/DE)*  Changing healthcare systems: what are convincing outcome measures?  *I. Durand-Zaleski (Paris/FR)* |
|  |  |
|  |  |
|  | 17:00-18:30, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 502** | **Getting IO into practice** |
|  |  |
|  | *Moderators: J. Lammer (Vienna/AT), R.A. Morgan (London/UK)* |
|  |  |
| 502.1    502.2    502.3    502.4    502.5 | Curriculum in IO  *P.P. Rao (Dombivli/IN)*  How to increase patient referral  *T.F. Jakobs (Munich/DE)*  Patient pathway in IO  *J. Ricke (Magdeburg/DE)*  Interaction with other disciplines  *J.I. Bilbao (Pamplona/ES)*  How do I promote IO services to my administration?  *R.-T. Hoffmann (Dresden/DE)* |
|  |  |
|  |  |
|  | 18:30-19:00 |
|  | **Satellite Symposia** |
|  |  |

TOP

**Monday, April 24**

|  |  |
| --- | --- |
|  |  |
|  | 07:45-08:15 |
|  | **Satellite Symposia** |
|  |  |
|  |  |
|  | 08:30-10:00, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 801** | **Lung metastases** |
|  |  |
|  | *Moderators: A. Gillams (London/UK), U. Martens (Heilbronn/DE)* |
|  |  |
| 801.1    801.2    801.3  801.4    801.5    801.6 | Rationale for local treatment – does it help patients?  *I. Gil-Bazo (Pamplona/ES)*  Resection – current status and evidence  *T. Treasure (London/UK)*  Invited scientific paper  SBRT – current status and evidence  *L.M. Kenny (Brisbane, QLD/AU)*  Thermal ablation – current status and evidence  *T. de Baère (Villejuif/FR)*  Round-table discussion |
|  |  |
|  |  |
|  | 08:30-10:00, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 802** | **Understanding tumour biology** |
|  |  |
|  | *Moderators: P. Gibbs (Melbourne, VIC/AU), N. Goldberg (Jerusalem/IL)* |
|  |  |
| 802.1    802.2    802.3    802.4    802.5 | Hypoxia and anoxia – friend or enemy?  *B.J. Wood (Bethesda, MD/US)*  IO procedures inducing tumour spread  *C.T. Sofocleous (New York, NY/US)*  Post-ablation inflammation and immune reactions – the bad  *N. Goldberg (Jerusalem/IL)*  Post-ablation inflammation and immune reactions – the good  *M.H.M.G.M. den Brok (Nijmegen/NL)*  Combined locoregional and systemic immunotherapy  *L. Tselikas (Villejuif/FR)* |
|  |  |
|  |  |
|  | 10:30-11:30, Main Auditorium |
| **HL 901** | **Honorary Lecture** |
|  |  |
|  | *Moderators: J.I. Bilbao (Pamplona/ES), E. Brountzos (Athens/GR)* |
|  |  |
|  | *Laudation: A. Gangi (Strasbourg/FR)* |
|  |  |
| 901.1 | Metastatic colorectal cancer and percutaneous thermal ablation:  a happy marriage?  *J. Palussière (Bordeaux/FR)* |
|  |  |
|  |  |
|  | 10:30-12:00, HDT Room |
|  | **Hands-on Device Training** |
| **TA-HDT 3** | **Tumour ablation – Microwave** |
|  |  |
|  | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|  |  |
|  |  |
|  | 11:30-12:00, Main Auditorium |
|  | **Paper Session** |
| **PS 902** | **The best IO papers of 2016** |
|  |  |
|  | *Moderators: J.I. Bilbao (Pamplona/ES), E. Brountzos (Athens/GR)* |
|  |  |
| 902.1 | Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response  *C.E.N.M. Rosenbaum, A.F. van den Hoven, M.N.G.J.A. Braat, M. Koopman,*  *M.G.E.H. Lam, B.A. Zonnenberg, H.M. Verkooijen, M.A.A.J. van den Bosch;*  *Utrecht/NL* |
| 902.2 | Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma  *R. Hickey, S. Mouli, L. Kulik, K. Desai, B. Thornburg, D. Ganger, T. Baker,*  *M. Abecassis, J. Ralph Kallini, A. Gabr, V.L. Gates, A.B. Benson III,*  *R.J. Lewandowski, R. Salem; Chicago, IL/US* |
| 902.3 | Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinoma  *K. Malagari, T. Kiakidis, M. Pomoni, H. Moschouris, E. Emmanouil,*  *T. Spiridopoulos, V. Sotirchos, S. Tandeles, D. Koundouras, A. Kelekis,*  *D. Filippiadis, A. Charokopakis, E. Bouma, A. Chatziioannou, S. Dourakis,*  *J. Koskinas, T. Karampelas, K. Tamvakopoulos, N. Kelekis, D. Kelekis;*  *Athens/GR* |
|  |  |
|  |  |
|  | 13:00-14:30 |
|  | **Satellite Symposia** |
|  |  |
|  |  |
|  | 15:00-16:30, Auditorium 2 |
|  | **Multidisciplinary Tumour Board** |
| **MTB 1101** | **Lung tumours – beyond the guidelines** |
|  |  |
|  | *Coordinator: J. Palussière (Bordeaux/FR)* |
|  |  |
|  | *Panellists: J. Aristu (Pamplona/ES), A. Gillams (London/UK),*  *J. Jougon (Pessac/FR), U. Martens (Heilbronn/DE)* |
|  |  |
|  |  |
|  | 15:00-16:30, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 1102** | **IO in HCC: early and intermediate** |
|  |  |
|  | *Moderators: R. Golfieri (Bologna/IT), B. Sangro (Pamplona/ES)* |
|  |  |
| 1102.1    1102.2    1102.3    1102.4    1102.5 | From Barcelona to Hong Kong: the HCC classifications  *B. Sangro (Pamplona/ES)*  What to do when on the waiting list for transplantation  *V. Mazzaferro (Milan/IT)*  Local ablation in early stage: do we compete with surgery?  *L. Crocetti (Pisa/IT)*  Intermediate stage: is there room for radioembolisation?  *R. Salem (Chicago, IL/US)*  Intermediate stage: what are the indications for combined therapy?  *T.F. Jakobs (Munich/DE)* |
|  |  |
|  |  |
|  | 15:00-16:30, HDT Room |
|  | **Hands-on Device Training** |
| **TA-HDT 4** | **Tumour ablation – Microwave** |
|  |  |
|  | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|  |  |
|  |  |
|  | 17:00-18:30, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 1201** | **IO in HCC: what's new?** |
|  |  |
|  | *Moderators: V. Mazzaferro (Milan/IT), J. Urbano (Madrid/ES)* |
|  |  |
| 1201.1    1201.2    1201.3    1201.4    1201.5    1201.6    1201.7 | Current status of classifying HCC and tailoring therapy: an update  *J.-F.H. Geschwind (New Haven, CT/US)*  New drugs in advanced HCC  *B. Sangro (Pamplona/ES)*  Bland embolisation vs. drug-eluting beads: the evidence  *K. Malagari (Athens/GR)*  RF vs. microwave in tumours up to 4 cm: the evidence  *A. Denys (Lausanne/CH)*  Cryoablation vs. RF  *P.B. Shyn (Boston, MA/US)*  SARAH trial  *V. Vilgrain (Clichy/FR)*  Idarubicin TACE  *B. Guiu (Montpellier/FR)* |
|  |  |
|  |  |
|  | 17:00-18:30, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 1202** | **Primary lung cancer** |
|  |  |
|  | *Moderators: G. Bastarrika (Pamplona/ES), J. Palussière (Bordeaux/FR)* |
|  |  |
| 1202.1    1202.2      1202.3  1202.4    1202.5    1202.6 | An update of systemic therapy of NSCLC  *U. Martens (Heilbronn/DE)*  Surgery, SBRT, local ablation: an appraisal of the pre- and post-treatment  lung function  *E. Quoix (Strasbourg/FR)*  Invited scientific paper  SBRT  *J. Aristu (Pamplona/ES)*  Local ablation  *X. Buy (Bordeaux/FR)*  Imaging follow-up of SBRT and ablation  *R.D. Suh (Los Angeles, CA/US)* |
|  |  |
|  |  |
|  | 18:30-19:00 |
|  | **Satellite Symposia** |
|  |  |

TOP

**Tuesday, April 25**

|  |  |
| --- | --- |
|  |  |
|  | 07:45-08:15 |
|  | **Satellite Symposia** |
|  |  |
|  |  |
|  | 08:30-10:00, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 1501** | **Breast cancer patients – the IO add-on** |
|  |  |
|  | *Moderators: E. Aranda (Córdoba/ES), F. Orsi (Milan/IT)* |
|  |  |
| 1501.1    1501.2    1501.3    1501.4  1501.5    1501.6 | Demographics and need for treatment  *A. Urrutikoetxea (San Sebastián/ES)*  Local treatment in metastatic breast cancer: the oncologist's perspective  *J.-E. Kurtz (Strasbourg/FR)*  Ablation of breast tumours  *J. Palussière (Bordeaux/FR)*  Invited scientific paper  IO in metastatic liver disease  *F. Orsi (Milan/IT)*  IO in metastatic bone disease  *D.K. Filippiadis (Athens/GR)* |
|  |  |
|  |  |
|  | 08:30-10:00, Main Auditorium |
|  | **Video Learning Session** |
| **VL 1502** | **How I do it – lung, kidney, bone** |
|  |  |
|  | *Moderators: X. Serrés (Barcelona/ES)*  *Commentator: D.J. Breen (Southampton/UK)* |
|  |  |
| 1502.1    1502.2    1502.3    1502.4 | Lung cryoablation  *F. Deschamps (Villejuif/FR)*  Kidney microwave ablation  *J.L. Hinshaw (Madison, WI/US)*  Bone consolidation  *J. Garnon (Strasbourg/FR)*  Thyroid radiofrequency ablation  *F. Stacul (Trieste/IT)* |
|  |  |
|  |  |
|  | 10:30-12:00, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 1601** | **MSK tumours beyond the spine** |
|  |  |
|  | *Moderators: M.R. Callstrom (Rochester, MN/US), A.D. Kelekis (Athens/GR)* |
|  |  |
| 1601.1    1601.2    1601.3  1601.4    1601.5    1601.6 | Bone consolidation in cancer patients: biomechanical and surgical  *P.J. Papagelopoulos (Athens/GR)*  Indications and limits of SBRT  *S. Myrehaug (Toronto, ON/CA)*  Invited scientific paper  Ablation and consolidation  *R.-T. Hoffmann (Dresden/DE)*  Management of benign bone tumours excluding osteoid osteoma  *J. Jennings (St. Louis, MO/US)*  Treatment options for soft tissue tumours  *X. Buy (Bordeaux/FR)* |
|  |  |
|  |  |
|  | 10:30-12:00, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 1602** | **Complication management** |
|  |  |
|  | *Moderators: P. Reimer (Karlsruhe/DE), O.M. van Delden (Amsterdam/NL)* |
|  |  |
| 1602.1    1602.2    1602.3    1602.4    1602.5    1602.6 | Liver thermal ablation  *L. Solbiati (Rozzano/IT)*  TACE  *Y. Arai (Tokyo/JP)*  Radioembolisation  *B. Peynircioglu (Ankara/TR)*  Kidney cryoablation  *D.J. Breen (Southampton/UK)*  Lung ablation  *R.D. Suh (Los Angeles, CA/US)*  Bone ablation  *J. Garnon (Strasbourg/FR)* |
|  |  |
|  |  |
|  | 10:30-12:00, HDT Room |
|  | **Hands-on Device Training** |
| **TA-HDT 5** | **Tumour ablation – Alternative techniques and image guidance** |
|  |  |
|  | [*Please click here for further details.*](http://www.ecio.org/index.php?pid=133) |
|  |  |
|  |  |
|  | 13:00-14:30 |
|  | **Satellite Symposia** |
|  |  |
|  |  |
|  | 15:00-16:30, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 1801** | **Genomics in cancer** |
|  |  |
|  | *Moderators: B. Costa-Silva (Lisbon/PT), R. Lencioni (Miami, FL/US)* |
|  |  |
| 1801.1    1801.2    1801.3    1801.4    1801.5 | Genomics – a general concept?  *R.B. Corcoran (Boston, MA/US)*  Is genomics changing the percutaneous biopsy business?  *G. Frija (Paris/FR)*  Radiomics in MRI  *D. Bonekamp (Heidelberg/DE)*  Radiomics – new markers in PET-CT  *N. Schäfer (Lausanne/CH)*  Iomics – what could it mean?  *R. Lencioni (Miami, FL/US)* |
|  |  |
|  |  |
|  | 15:00-16:30, Main Auditorium |
|  | **Video Learning Session** |
| **VL 1802** | **How I do it – liver** |
|  |  |
|  | *Moderator: A. Denys (Lausanne/CH)*  *Commentator: P.E. Huppert (Darmstadt/DE)* |
|  |  |
| 1802.1    1802.2    1802.3    1802.4    1802.5 | Complex liver thermal ablation  *P. Chevallier (Nice/FR)*  Liver DEB-TACE  *R. Golfieri (Bologna/IT)*  Liver balloon TACE  *T. de Baère (Villejuif/FR)*  Liver radioembolisation  *P. Reimer (Karlsruhe/DE)*  Portal vein and hepatic vein embolisation  *R. Duran (Lausanne/CH)* |
|  |  |
|  |  |
|  | 17:00-18:30, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 1901** | **Spinal tumours** |
|  |  |
|  | *Moderators: A. Gangi (Strasbourg/FR), J.W. Jennings (Saint Louis, MO/US)* |
|  |  |
| 1901.1    1901.2    1901.3  1901.4    1901.5    1901.6 | Spinal surgery in cancer patients  *J.-P. Steib (Strasbourg/FR)*  Indications and limits of SBRT  *L.M. Kenny (Brisbane, QLD/AU)*  Invited scientific paper  Ablation and augmentation  *J. Jennings (St. Louis, MO/US)*  Management of benign tumours  *A.D. Kelekis (Athens/GR)*  The role of embolisation  *L. Hechelhammer (St. Gallen/CH)* |
|  |  |
|  |  |
|  | 17:00-18:30, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 1902** | **Promoting IO evidence** |
|  |  |
|  | *Moderators: L. Donoso (Barcelona/ES), P.L. Pereira (Heilbronn/DE)* |
|  |  |
| 1902.1    1902.2    1902.3    1902.4    1902.5 | CIRT  *J.I. Bilbao (Pamplona/ES)*  CIREL  *P.L. Pereira (Heilbronn/DE)*  Overview ongoing studies  *V. Vilgrain (Clichy/FR)*  How to bring a product to market?  *N.T. Lange (Bonn/DE)*  The value of registries vs. randomised trials  *G.J. Poston (Liverpool/UK)* |
|  |  |
|  |  |
|  | 18:30-19:00 |
|  | **Satellite Symposia** |
|  |  |

TOP

**Wednesday, April 26**

|  |  |
| --- | --- |
|  |  |
|  | 08:30-10:00, Main Auditorium |
|  | **Clinical Focus Session** |
| **CF 2101** | **Kidney tumours** |
|  |  |
|  | *Moderators: J.C. Durack (New York, NY/US), D.K. Filippiadis (Athens/GR)* |
|  |  |
| 2101.1    2101.2    2101.3    2101.4    2101.5 | Demographics and need for treatment  *J.E. Robles (Pamplona/ES)*  Evidence-based nephron-sparing surgery  *B.W. Lagerveld (Amsterdam/NL)*  Evidence-based ablation vs. resection outcomes  *D.J. Breen (Southampton/UK)*  Palliative intervention in metastatic renal tumours  *M.R. Callstrom (Rochester, MN/US)*  The CIRSE SOP paper on RCC (cT1a)  *M.E. Krokidis (Cambridge/UK)* |
|  |  |
|  |  |
|  | 08:30-10:00, Auditorium 2 |
|  | **Clinical Focus Session** |
| **CF 2102** | **Recipes for general patient management** |
|  |  |
|  | *Moderators: P.E. Bize (Genolier/CH), F. Orsi (Milan/IT)* |
|  |  |
| 2102.1    2102.2    2102.3    2102.4    2102.5    2102.6 | Assessing the patient's general condition  *M. Fuchs (Munich/DE)*  Analgosedation vs. ITN  *R. Bale (Innsbruck/AT)*  Peri-interventional pain management  *A. Vari (Rome/IT)*  Peri-interventional antibiotics  *G. Maleux (Leuven/BE)*  Anticoagulation and anti-aggregants: how to deal with them  *J.A. Páramo (Pamplona/ES)*  Postembolisation syndrome management  *B. Gebauer (Berlin/DE)* |
|  |  |
|  |  |
|  | 10:00-10:45 |
|  | **Satellite Symposium** |
|  |  |
|  |  |
|  | 11:15-12:45, Main Auditorium |
| **MM 2201** | **Morbidity & Mortality Conference** |
|  |  |
|  | *Coordinators: M. Burrel (Barcelona/ES), P. Chevallier (Nice/FR)* |
|  |  |